Eos Advisory is a hands-on, early-stage and growth investor focused on science and technology innovations addressing societal and environmental issues.
Portfolio
9
companies
Chromacity
Chromacity designs and manufactures advanced ultrafast pulsed fibre lasers for scientific and industrial research.
Neupulse
Neupulse develops a non-drug wristband therapy to help manage Tourette syndrome.
Cumulus Oncology
Cumulus Oncology builds spin-out companies to accelerate the development of new cancer treatments.
Bioliberty
Bioliberty builds soft robotic gloves and digital therapy platforms for stroke rehabilitation.
Dxcover
Dxcover develops blood tests using infrared spectroscopy and artificial intelligence to detect cancer early.
Waire Health
Waire Health builds autonomous remote patient monitoring sensors for healthcare providers.
Wobble Genomics
Wobble Genomics develops a novel approach to RNA sequencing for biotechnology applications.
ClinSpec Diagnostics
ClinSpec Diagnostics develops rapid liquid biopsies for early cancer detection.
RAB-Microfluidics
RAB-Microfluidics develops microfluidic technology to automate and accelerate oil analysis for industrial machinery.
Andrew McNeill
Andrew serves as managing partner at Eos Advisory and holds investor director roles at Cumulus Oncology and Clinspec Diagnostics Limited. His background includes chief executive and chair positions at Fixed Phage and Chromacity.
LinkedInMark Beaumont
Partner
Andrew McNeil
Managing Partner
Ana Stewart
Partner
The Scottish laser technology specialist has raised over £1m from existing investors and Innovate UK to fund healthcare product rollouts and emissions monitoring tools.
"Designing and manufacturing state-of-the-art ultrafast infra-red lasers brings huge value and efficiencies to the global healthcare market. Our new '920' builds on a decade of research and IP development to extend our product roadmap."
The seed round was led by Eos Advisory with US investor backing to support regulatory approval across international markets.
The funding round was led by Eos Advisory and includes participation from the Scottish National Investment Bank.
"This funding round marks an important milestone for Cumulus, as oncology remains a critical area of scientific innovation and unmet medical need. At Cumulus, we're not only innovating at the scientific level but also offering a uniquely differentiated process for decision-making and prioritisation in drug discovery and development. The business model enables only the strongest science to be translated from discovery into clinical trials. Our portfolio approach aims to enhance the ultimate success rate in cancer therapy development, which currently remains unacceptably low. It also provides an alternative approach to the de-risking of early-stage oncology investment. We are grateful for the support from Eos and the Scottish National Investment Bank enabling us to continue investing in our existing companies and expand our portfolio of new biotechs, advancing our mission to develop the next generation of cancer therapies."
The funding round was led by Archangels to support product development and US commercialisation.
"Bioliberty has developed a highly effective solution for helping patients with hand weakness, with the potential to improve the quality of life for millions worldwide. We believe its technology has far-reaching benefits beyond this first application, providing the business with an excellent opportunity to grow quickly from its base here in Scotland. Archangels is excited to be supporting the team as they finalise what we hope will be the first of many products and start scaling up their sales activity."
The funding round was backed by a group of existing investors alongside a grant from the European Innovation Council.
"This is a very significant funding milestone in our mission to detect cancer early and improve survival and quality of life for patients. Having demonstrated our multi-cancer capability, we can now focus on building the pipeline of organ-specific tests, beginning with a multi-center study to gain regulatory approval for the brain cancer test. We will also expand our data on colorectal cancer, one of the leading causes of death worldwide, and continue our work on collaborative projects."
The funding round will support production scaling, team expansion, and international market entry.
The funding round was led by Eos Advisory alongside Old College Capital as part of a wider £2.2m seed financing.
"There is a huge global market of scientists and clinicians who would buy our products as part of their sequencing work."
Norcliffe Capital led the latest investment as the cancer diagnostics firm reached its £3.5m target.
"Achieving the £3.5m target enables us to accelerate our plans. We will shortly complete our move into new lab and office facilities and increase staffing to 15, bringing forward key operational and commercial appointments."
The financing round was led by Eos Advisory with participation from Newable Ventures and Scottish Enterprise.
"We are revolutionising oil test ing and analysis services by making conventional laboratory procedures mobile, rapid and routine"
